. Author manuscript; available in PMC: 2021 Apr 20.

Published in final edited form as: Chem Res Toxicol. 2020 Mar 20;33(4):855–859. doi: 10.1021/acs.chemrestox.0c00086

Table 2.

Notable Products Transitioned from the NIH to BARDA for Advanced Development[5]

Drug	Putative Mechanism(s) of Action	Awardee	Proposed MCM Indication
Galantamine	Reversible Acetylcholinesterase (AChE) inhibitor and potentiating ligand of nicotinic Acetylcholine receptors (nAChRs)	CounterVail Corporation	Nerve agent-induced seizures and neuronal degeneration
Midazolam (Seizalam®)	Allosteric potentiation of synaptic Gamma aminobutyric acid (GABA)-A receptors	Meridian Medical Technologies, a Pfizer subsidiary	Status epilepticus in adults (including seizure induced by nerve agents)
Alteplase (Activase®)	Fibrinolytic agent	Genentech	Sulfur mustard-induced pulmonary injuries
R-107	Bifunctional nitric oxide donor and redox degradation catalyst	Radikal Therapeutics, Inc.	Chlorine (Cl₂)-induced inhalational lung injury (CILI)
GSK2798745	Transient Receptor Potential cation channel V4 (TRPV4) Antagonist	GSK	Acute Respiratory Distress Syndrome (ARDS) due to chlorine gas inhalation
Tezampanel	Glutamate Kainate Receptors (GluR5) Antagonist	Proniras Corporation	Treatment of benzodiazepine-refractory seizures induced by nerve agents